In a cost-effectiveness analysis comparing traditional bariatric surgery and GLP-1 agonist use for obesity management, the monthly cost based on 2023 pricing for both non-compounded SMA and liraglutide was approximately $1600 monthly [21]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.